Atara Biotherapeutics, Inc. (AT2.F)
- Previous Close
0.6512 - Open
0.6188 - Bid 0.6426 x --
- Ask 0.6496 x --
- Day's Range
0.6188 - 0.6188 - 52 Week Range
0.1795 - 2.6920 - Volume
3,860 - Avg. Volume
1,698 - Market Cap (intraday)
76.771M - Beta (5Y Monthly) 0.72
- PE Ratio (TTM)
-- - EPS (TTM)
-2.4300 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
33.38
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
www.atarabio.comRecent News: AT2.F
Performance Overview: AT2.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AT2.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AT2.F
Valuation Measures
Market Cap
76.77M
Enterprise Value
82.50M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.20
Price/Book (mrq)
--
Enterprise Value/Revenue
9.62
Enterprise Value/EBITDA
-0.31
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-62.11%
Return on Equity (ttm)
-2,014.86%
Revenue (ttm)
8.57M
Net Income Avi to Common (ttm)
-276.13M
Diluted EPS (ttm)
-2.4300
Balance Sheet and Cash Flow
Total Cash (mrq)
51.73M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-55.72M
Research Analysis: AT2.F
Company Insights: AT2.F
AT2.F does not have Company Insights